Browsing Tag
China National Medical Products Administration
4 posts
HUTCHMED gets priority review for fanregratinib in FGFR2-positive cholangiocarcinoma in China
HUTCHMED’s fanregratinib gains NDA acceptance with priority review in China. Find out what it means for FGFR2-driven cancers and precision oncology adoption.
GSK’s Shingrix wins China approval for adults 18+ — Can this vaccine expansion reignite its global growth story?
Find out how GSK’s Shingrix approval in China for adults aged 18+ could reshape its vaccine business and investor confidence. #GSK #Shingrix
Breakthrough in cancer treatment: China approves PADCEV for advanced urothelial cancer
China’s National Medical Products Administration (NMPA) has granted approval for PADCEV (enfortumab vedotin) to treat locally advanced or…
Chinese regulator accepts NDA of BeiGene’s pamiparib in ovarian cancer
BeiGene said that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has…